Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507030 | PMC |
| http://dx.doi.org/10.1111/mcn.13021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on 'Musculoskeletal Ultrasound Assessment of the Clinical Efficacy of the Combination of Acupressure and "Three Methods of Neck Movement (TCM)" Therapy in the Treatment of Cervical Spondylosis: A Study Protocol for a Randomized Controlled Trial' [Response to Letter].
J Pain Res
December 2024
Massage Department, Zhejiang Hospital, Hangzhou City, People's Republic of China.
Arimoclomol: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Arimoclomol (MIPLYFFA™), an oral small molecule that crosses the blood brain barrier and is thought to upregulate CLEAR (Coordinated Lysosomal Expression and Regulation) network genes and improve lysosomal function, is being developed by Zevra Therapeutics Inc., for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). In September 2024, arimoclomol was approved for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older in the USA.
View Article and Find Full Text PDFXanomeline/Trospium Chloride: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Xanomeline/trospium chloride (COBENFY™), formerly KarXT, is a first-in-class, oral, fixed-dose muscarinic agonist/antagonist combination being developed for use in schizophrenia and Alzheimer's disease psychosis. Xanomeline is thought to confer efficacy by acting as an agonist at M and M muscarinic acetylcholine receptors in the brain, and trospium chloride reduces the peripheral cholinergic adverse events associated with xanomeline. Xanomeline/trospium chloride received its first approval on 26 September 2024 in the USA for the treatment of schizophrenia in adults.
View Article and Find Full Text PDFCombination of ATRAP deletion and angiotensin II accelerates DKD progression, which may also accelerate DKD research.
Hypertens Res
December 2024
Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
Patients' perspectives regarding health professionals contacting their relatives about genetic risk directly (with patient consent).
Eur J Hum Genet
December 2024
Centre for Law and Genetics, University of Tasmania, Hobart, TAS, Australia.
Genetic testing of blood relatives of individuals at high risk of dominant conditions has significant preventive health benefits. However, cascade testing uptake is <50%. Research shows increased testing uptake when health professionals (HPs) contact at-risk relatives directly, with patient consent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!